| Castro, Mario |
| Completed | 4 | 40 | Europe, US | dupilumab, Dupixent®, SAR231893, Matching placebo | Regeneron Pharmaceuticals | Asthma | 07/23 | 07/23 | | |
| Recruiting | 4 | 1250 | US | Roflumilast, Daliresp, Azithromycin, Zithromax | Johns Hopkins University, Patient-Centered Outcomes Research Institute, University of Illinois at Chicago | Chronic Obstructive Pulmonary Disease Severe, Chronic Bronchitis | 03/26 | 05/26 | | |
| Recruiting | 4 | 81 | Europe, Canada, US | Benralizumab, Placebo | AstraZeneca | Asthma | 09/26 | 09/26 | | |
| Recruiting | 2 | 380 | US | IVIG + Coordinated Care, IVIG Placebo + Coordinated Care, Ivabradine + Coordinated Care, Ivabradine Placebo + Coordinated Care, IVIG + Usual Care, IVIG Placebo + Usual Care, Ivabradine + Usual Care, Ivabradine Placebo + Usual Care | Kanecia Obie Zimmerman | Long COVID, Long Covid19, Long Covid-19 | 12/25 | 03/26 | | |
| Active, not recruiting | 2 | 964 | US | Experimental: Paxlovid 25 day dosing, Experimental: Paxlovid 15 day dosing, Placebo Comparator: Control | Kanecia Obie Zimmerman | Long COVID, Long Covid19 | 08/24 | 03/25 | | |
NCT04129931: PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study |
|
|
| Active, not recruiting | 2 | 395 | US | MCT, Breathe Better Diet (BBD), Clazakizumab, Anti-interleukin 6 monoclonal antibody, Anti-IL-6 mAb, BMS-945429, ALD518, Broncho-Vaxom, OM-85 BV VEGETAL, Imatinib Mesylate, Gleevec, Zoleta, Glivec, Ziatir, Cavosonstat, N91115, Placebo | University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI) | Asthma | 12/24 | 12/24 | | |
NCT05707507: Implementation of an Outpatient Parenteral Antimicrobial Therapy Program |
|
|
| Recruiting | N/A | 40 | RoW | Place of treatment | Hospital Universitario Dr. Jose E. Gonzalez | Outpatient | 01/24 | 01/24 | | |
| Recruiting | N/A | 1000 | US | | Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI), American Lung Association, University of Vermont | Lung Diseases | 07/26 | 07/26 | | |
RheSolve, NCT04677465: Clinical Study of the RheOx Bronchial Rheoplasty System in Treating the Symptoms of Chronic Bronchitis |
|
|
| Active, not recruiting | N/A | 270 | Europe, US | RheOx Bronchial Rheoplasty, Sham Procedure | Gala Therapeutics, Inc. | Chronic Bronchitis | 05/24 | 10/25 | | |
NCT04543461: American Lung Association (ALA) Lung Health Cohort |
|
|
| Recruiting | N/A | 4000 | US | | Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI), American Lung Association, Stanford University | Lung Diseases | 09/26 | 09/26 | | |
NCT05172024: Understanding the Long-term Impact of COVID-19 in Adults (RECOVER) |
|
|
| Active, not recruiting | N/A | 15178 | US | | NYU Langone Health, National Heart, Lung, and Blood Institute (NHLBI) | SARS-CoV2 Infection | 04/25 | 05/25 | | |
| Active, not recruiting | N/A | 1100 | US | | Milton S. Hershey Medical Center, National Heart, Lung, and Blood Institute (NHLBI) | Asthma | 06/26 | 12/26 | | |
| McGuirk, Joseph |
| Recruiting | 3 | 1400 | Europe, Canada, Japan, US, RoW | Previously treated CAR-T patients | Novartis Pharmaceuticals, University of Pennsylvania | Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program | 02/36 | 02/36 | | |
FIRCE-1, NCT05972720: A Phase 2 Study of Firi-cel in Patients with Relapsed/refractory Large B-cell Lymphoma |
|
|
| Recruiting | 2 | 123 | US | Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug) | CARGO Therapeutics | Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) | 09/25 | 12/26 | | |
FELIX, NCT04404660: A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) |
|
|
| Active, not recruiting | 1/2 | 153 | NA | AUTO1, Obecabtagene autoleucel (obe-cel) | Autolus Limited | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | 05/25 | 05/25 | | |
|
CARBON, NCT04035434: A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies |
|
|
| Terminated | 1/2 | 62 | Europe, Canada, US, RoW | CTX110 | CRISPR Therapeutics AG | B-cell Malignancy, Non-Hodgkin Lymphoma, B-cell Lymphoma, Adult B Cell ALL | 10/24 | 10/24 | | |
NCT03158896: Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease |
|
|
| Recruiting | 1 | 10 | US | MSCTC-0010 Dose Escalation, MSCTC-0010 | University of Kansas Medical Center | Acute Graft Versus Host Disease | 08/25 | 08/25 | | |
| Recruiting | 1 | 38 | US | EAGD T-cell infusion (Phase I), CliniMACS-Prodigy, CliniMACS Alpha Beta T-Cell Depletion System, EAGD T-cell infusion (Expansion) | University of Kansas Medical Center, In8bio Inc. | Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes | 01/24 | 01/25 | | |
OGFT001-001, NCT03802695: A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies |
|
|
| Recruiting | 1 | 186 | US | OrcaGraft (Orca-Q) | Orca Biosystems, Inc. | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Myelofibrosis, Chronic Myeloid Leukemia | 04/26 | 04/28 | | |
| Active, not recruiting | 1 | 16 | US, RoW | SC291, Cyclophosphamide, Fludarabine | Sana Biotechnology | Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | 11/25 | 11/38 | | |
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) |
|
|
| Recruiting | N/A | 99999 | US | A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) | Center for International Blood and Marrow Transplant Research, National Marrow Donor Program | Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia | 10/41 | 10/41 | | |
| Neupane, Prakash C |
| Active, not recruiting | 1/2 | 200 | Europe, US | HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab., HB-202 / HB-201 alternating intravenous administration + pembrolizumab., HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab., HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C) | Hookipa Biotech GmbH, Hookipa Biotech | HPV-Related Squamous Cell Carcinoma | 06/25 | 06/26 | | |
NCT03803774: Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma |
|
|
| Terminated | 1 | 13 | US | Birinapant, TL32711, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Tumor Biopsy, PET Scan, Positron emission tomography scan, CT Scan, Computed tomography scan, MRI Scan, Magnetic resonance scan | National Cancer Institute (NCI) | Locally Recurrent Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma, Sinonasal Squamous Cell Carcinoma | 11/23 | 12/23 | | |
| Burns, Jeffrey |
| Terminated | 3 | 1027 | Europe, Canada, Japan, US, RoW | Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo | Biogen, Biogen Idec Research Limited | Alzheimer's Disease | 08/24 | 08/24 | | |
| Completed | 1/2 | 46 | US | Dapagliflozin, Farxiga, Placebo | Jeff Burns, MD | Alzheimer Disease | 07/22 | 07/22 | | |
| Completed | 1 | 243 | US | Alianza Latina | University of Kansas Medical Center, National Institute on Minority Health and Health Disparities (NIMHD) | Dementia | 08/24 | 08/24 | | |
NCT03253341: Prescribing Smart Aging: Integrating Health Systems With Community-Based Lifestyle Interventions |
|
|
| Completed | N/A | 219 | US | Smart Aging Program, Educational Materials | University of Kansas Medical Center | Aging, Health Behavior | 06/21 | 08/23 | | |
| Recruiting | N/A | 2000 | Canada, US | | University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute | Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD) | 12/24 | 12/24 | | |
vCCC 2, NCT05138601: Remote Monitoring and Virtual Collaborative Care for Hypertension Control to Prevent Cognitive Decline Phase II |
|
|
| Active, not recruiting | N/A | 1000 | US | Virtual Collaborative Care Clinic | University of Kansas Medical Center, University of Utah, University of Missouri-Columbia | Hypertension | 09/26 | 12/26 | | |
| Recruiting | N/A | 1500 | Canada, US | Neuraceq, Florbetaben, Amyvid, Florbetapir, Tauvid, Flortaucipir, 18F-AV-1451, AV-1451, MK-6240, florquinitau F-18, [18F]MK-6240, NAV4694, [18F]NAV4694, [18F]AZD4694, PI-2620, [18F]PI-2620 | University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute | Mild Cognitive Impairment, Alzheimer Disease, Dementia | 07/27 | 07/27 | | |
| Bajaj, Jasmohan S |
NCT01846663: Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy |
|
|
| Terminated | 4 | 6 | US | Placebo, Rifaximin, XIFAXAN® Tablets | Bausch Health Americas, Inc. | Hepatic Encephalopathy | 02/16 | 02/16 | | |
SACRED, NCT03654053: Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis |
|
|
| Active, not recruiting | 3 | 142 | US | Placebo Oral Tablet, Placebo, Simvastatin 40mg, Simvastatin | VA Office of Research and Development | Cirrhosis | 12/25 | 12/25 | | |
| Recruiting | 3 | 380 | Europe, US | SMT + PE-A 5%, Albutein 5%, Standard Medical Treatment, SMT | Grifols Therapeutics LLC, Instituto Grifols, S.A. | Acute-On-Chronic Liver Failure | 10/26 | 10/26 | | |
| Completed | 2 | 30 | US | Rifamycin SV MMX, Aemcolo, Placebo | Hunter Holmes Mcguire Veteran Affairs Medical Center | Hepatic Encephalopathy, Cirrhosis, Liver | 04/23 | 04/23 | | |
STARLIGHT, NCT06613698: A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease |
|
|
| Not yet recruiting | 2 | 393 | Europe, Canada, Japan, US, RoW | GSK4532990, Placebo | GlaxoSmithKline | Liver Diseases, Alcoholic | 12/26 | 03/27 | | |
| Recruiting | 2 | 30 | US | Albumin Infusion, Albutein | Hunter Holmes Mcguire Veteran Affairs Medical Center, Grifols Biologicals, LLC | Cirrhosis, Hepatic Encephalopathy | 03/25 | 06/25 | | |
| Completed | 1/2 | 60 | US | Fecal Microbial transplant Capsules, Fecal Microbial Transplant Enema, Placebo | VA Office of Research and Development | Cirrhosis, Hepatic Encephalopathy | 12/23 | 12/23 | | |
| Recruiting | 1/2 | 20 | US | Rifaximin SSD 40 mg IR tablet, Placebo | Jasmohan Bajaj, Bausch Health Companies, INC. | Dementia Alzheimer Type, Dementia Associated With Cerebrovascular Disease | 12/25 | 05/26 | | |
| Recruiting | 1/2 | 80 | US | Intestinal Microbiota Transplant (IMT) Capsules, Placebo Capsules | Virginia Commonwealth University, National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Liver Disease; Alcohol-Related, Cirrhosis, Alcohol Use Disorder | 11/26 | 12/26 | | |
NCT05376488: Effect of Brief Dietary Intervention on Ammonia Levels |
|
|
| Completed | N/A | 30 | US | One meal | Hunter Holmes Mcguire Veteran Affairs Medical Center | Cirrhosis, Hepatic Encephalopathy | 12/22 | 04/23 | | |
NCT05538962: Longitudinal Monitoring of Inflammation in Cirrhosis |
|
|
| Completed | N/A | 85 | US | Sensor skin | Hunter Holmes Mcguire Veteran Affairs Medical Center | Cirrhosis, Liver | 09/23 | 07/24 | | |
NCT05604274: Longitudinal Monitoring of Stool Characteristics |
|
|
| Completed | N/A | 60 | US | App to monitor stool consistency and symptoms | Hunter Holmes Mcguire Veteran Affairs Medical Center | Cirrhosis, Liver | 10/23 | 10/23 | | |
NCT03564626: Health IT Generated PROs to Improve Outcomes in Cirrhosis |
|
|
| Completed | N/A | 464 | US | Health-IT +/- Scheduled Follow Up | Virginia Commonwealth University, Agency for Healthcare Research and Quality (AHRQ) | Cirrhosis | 04/24 | 05/24 | | |
| Recruiting | N/A | 30 | US | Resistant potato starch, Powdered cellulose | Hunter Holmes Mcguire Veteran Affairs Medical Center | Cirrhosis, PTSD | 06/25 | 09/25 | | |
| Recruiting | N/A | 100 | US | Dental exam and periodontal cleaning if needed | Hunter Holmes Mcguire Veteran Affairs Medical Center, Virginia Commonwealth University, Bausch & Lomb Incorporated | Cirrhosis, Periodontal Diseases | 10/24 | 12/24 | | |
| Jackson, Robert M |
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 2 | 75 | US | TTI-101, Placebo | Tvardi Therapeutics, Incorporated | Idiopathic Pulmonary Fibrosis | 03/25 | 07/25 | | |
NCT05962606: Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia. |
|
|
| Recruiting | 2 | 150 | Europe | AON-D21, Placebo | Aptarion Biotech AG | Community-acquired Pneumonia | 05/26 | 06/26 | | |
NCT05571059: Oral Ifetroban in Patients with Idiopathic Pulmonary Fibrosis (IPF) |
|
|
| Recruiting | 2 | 128 | US | Ifetroban Sodium, ifetroban, Placebo | Cumberland Pharmaceuticals | Idiopathic Pulmonary Fibrosis | 01/26 | 01/26 | | |
| Recruiting | N/A | 1017 | US, RoW | Infuse™ Bone Graft (Infuse™), Intervertebral body fusion device and Medtronic posterior Fixation Systems | Medtronic Spinal and Biologics | Degenerative Disease of the Lumbosacral Spine | 04/26 | 04/28 | | |
| Nick, Jerry A |
NCT06159725: A Study to Evaluate the Safety of CMTX-101 in People with Cystic Fibrosis |
|
|
| Recruiting | 1/2 | 41 | US | CMTX-101, Placebo | Clarametyx Biosciences, Inc. | Persistent Infection, Cystic Fibrosis | 08/25 | 08/25 | | |
| Recruiting | N/A | 300 | Canada, US | | University of British Columbia, Arizona State University, Children's Hospital Colorado, National Heart, Lung, and Blood Institute (NHLBI), Cystic Fibrosis Foundation | Cystic Fibrosis | 11/24 | 12/24 | | |
STEADY, NCT05822102: Simultaneous quanTification of Elexacaftor/tezAcaftor/Ivacaftor Via Reverse Phase High Performance liquiD chromatographY |
|
|
| Enrolling by invitation | N/A | 100 | US | | National Jewish Health | Cystic Fibrosis | 09/23 | 09/23 | | |
| Enrolling by invitation | N/A | 10 | US | mycobacteriophage | National Jewish Health, Cystic Fibrosis Foundation | Cystic Fibrosis, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection, Mycobacterium Infections, Mycobacterium; Pulmonary | 12/26 | 12/28 | | |
| Enrolling by invitation | N/A | 220 | US | urine lipoarabinomannan (LAM) | Jerry A. Nick, M.D. | Cystic Fibrosis | 10/25 | 10/25 | | |
| Enrolling by invitation | N/A | 200 | US | | National Jewish Health, Cystic Fibrosis Foundation, Children's Hospital Colorado | Cystic Fibrosis | 03/25 | 03/25 | | |
| Enrolling by invitation | N/A | 70 | US | | National Jewish Health, Cystic Fibrosis Foundation, Children's Hospital Colorado | Cystic Fibrosis | 03/25 | 03/25 | | |
| Holzbeierlein, Jeffrey M |
| Recruiting | N/A | 20 | US | SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors, TURBT En Bloc | University of Kansas Medical Center | Bladder Cancer, Surgery | 12/24 | 12/24 | | |
| Recruiting | N/A | 4400 | US | Hexaminolevulinate hydrochloride (HCL), Cysview®, Hexvix®, Karl Storz D-Light C Photodynamic Diagnostic (PDD) system | Photocure, Catalyst Pharmaceutical Research | Bladder Cancer | 12/28 | 12/28 | | |
| Make, Barry |
| Recruiting | N/A | 1000 | US | | Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI), American Lung Association, University of Vermont | Lung Diseases | 07/26 | 07/26 | | |
NCT04543461: American Lung Association (ALA) Lung Health Cohort |
|
|
| Recruiting | N/A | 4000 | US | | Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI), American Lung Association, Stanford University | Lung Diseases | 09/26 | 09/26 | | |
NCT06404073: RECOVER-ENERGIZE Platform Protocol_Appendix B (Structured Pacing (PEM)) |
|
|
| Recruiting | N/A | 300 | US | Structured Pacing, Usual Care | Duke University, National Heart, Lung, and Blood Institute (NHLBI) | Long COVID, Long Covid19, Long Covid-19 | 10/25 | 01/26 | | |
NCT06404060: RECOVER-ENERGIZE Platform Protocol_Appendix A (Exercise Intolerance) |
|
|
| Recruiting | N/A | 360 | US | Personalized Cardiopulmonary Rehabilitation, Education | Duke University, National Heart, Lung, and Blood Institute (NHLBI) | Long COVID, Long Covid19, Long Covid-19 | 10/25 | 01/26 | | |
| Recruiting | N/A | 660 | US | Personalized Cardiopulmonary Rehabilitation, Structured Pacing, Education, Usual Care | Duke University, National Heart, Lung, and Blood Institute (NHLBI) | Long COVID, Long Covid19, Long Covid-19 | 10/25 | 01/26 | | |
NCT05313087: COVID-19 Vaccine Response in Chronic Respiratory Conditions |
|
|
| Recruiting | N/A | 600 | US | COVID-19 vaccine | National Jewish Health | SARS-CoV Infection | 12/24 | 12/24 | | |
| Investigator, Principal |
| Completed | 4 | 144 | Europe | Opicapone 50 mg, BIA 9-1067, Placebo | Bial - Portela C S.A., Bial - Portela & Ca, S.A. | Parkinson Disease | 02/24 | 02/24 | | |
NCT04248205: Ketamine for Post-operative Analgesia in Hemorrhoidectomy |
|
|
| Recruiting | 4 | 100 | US | Ketamine | University of Oklahoma | Hemorrhoids | 01/25 | 07/25 | | |
NCT05400369: A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease |
|
|
| Completed | 4 | 140 | RoW | Sitafloxacin, Gracevit, Moxifloxacin Hydrochloride, Avelox | Daiichi Sankyo | COPD Exacerbation Acute | 09/24 | 09/24 | | |
TrEAT_TD2, NCT05677282: Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, with Loperamide Adjunct |
|
|
| Recruiting | 4 | 150 | RoW | Rifaximin 550 MG, Azithromycin 500 MG, Loperamide | Henry M. Jackson Foundation for the Advancement of Military Medicine, Infectious Diseases Clinical Research Program, Uniformed Services University of the Health Sciences | Diarrhoea;Acute, Diarrhea Travelers | 09/25 | 12/25 | | |
NCT06397781: Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients |
|
|
| Not yet recruiting | 4 | 100 | US | Skin Cleanser Combination No.1 | Boston Children's Hospital | Atopic Dermatitis | 12/28 | 12/28 | | |
NCT06793358: Use of Remimazolam and Fentanyl for Procedural Sedation in Patients Undergoing Dental Extraction |
|
|
| Not yet recruiting | 4 | 40 | US | fentanyl and Remimazolam | Indiana University, Indiana University Health | Dental Extraction | 01/26 | 03/26 | | |
POUR, NCT04994431: Post-Operative Urinary Retention () in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin |
|
|
| Terminated | 4 | 109 | US | Tamsulosin Hydrochloride | University of Massachusetts, Worcester, UMass Memorial Health Care | Thoracic Diseases, Urinary Retention | 10/23 | 10/23 | | |
NCT02932410 / 2016-001062-28: A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) |
|
|
| Active, not recruiting | 3 | 165 | Europe, Canada, US, RoW | Macitentan, ACT-064992, Standard-of-care | Actelion | Pulmonary Arterial Hypertension | 08/24 | 07/25 | | |
| Active, not recruiting | 3 | 590 | Europe, Canada, Japan, US, RoW | DS-1062a, Datopotamab deruxtecan (Dato-DXd), Docetaxel | Daiichi Sankyo, AstraZeneca | Non-small Cell Lung Cancer | 05/24 | 06/25 | | |
|
|
IDeate-Lung02, NCT06203210: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 540 | Europe, Canada, Japan, US, RoW | Ifinatamab deruxtecan, I-DXd, Topotecan, Amrubicin, Lurbinectedin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Small Cell Lung Cancer | 04/27 | 02/29 | | |
TNX-N, NCT03503136: Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC |
|
|
| Not yet recruiting | 3 | 632 | RoW | docetaxel, nedaplatin, and capecitabine, TNX induction chemotherapy, nedaplatin, N, docetaxel, cisplatin, and fluorouracil, TPF induction chemotherapy, cisplatin, P, docetaxel, cisplatin, and capecitabine, TPX induction chemotherapy, docetaxel, nedaplatin, and fluorouracil, TNF induction chemotherapy | Sun Yat-sen University, Tongji Hospital, Wuhan Union Hospital, China, Peking University, Air Force Military Medical University, China, Second Affiliated Hospital of Soochow University, The First Affiliated Hospital of Guangdong Pharmaceutical University, First People's Hospital of Foshan, Fifth Affiliated Hospital, Sun Yat-Sen University, Cancer Hospital of Guizhou Province, Xiangya Hospital of Central South University, Jilin Provincial Tumor Hospital, Henan Cancer Hospital, Hunan Cancer Hospital, Cancer Hospital of Guangxi Medical University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhejiang Cancer Hospital | Nasopharyngeal Carcinoma | 06/24 | 06/26 | | |
NCT05839899: Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location |
|
|
| Recruiting | 3 | 50 | US | Mifepristone plus one dose Misoprostol, Mifepristone plus two doses Misoprostol | Planned Parenthood League of Massachusetts | Abortion | 07/24 | 09/24 | | |
| Active, not recruiting | 3 | 586 | Europe, Canada, Japan, US, RoW | Patritumab Deruxtecan, HER3-DXd, U3-1402, Platinum-based chemotherapy | Daiichi Sankyo, Merck Sharp & Dohme LLC | Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion | 05/24 | 06/26 | | |
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy |
|
|
| Recruiting | 3 | 102 | Europe, Canada, US, RoW | Ampreloxetine, TD-9855, Placebo | Theravance Biopharma | Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy | 12/24 | 01/27 | | |
| Not yet recruiting | 3 | 615 | RoW | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection | Beijing VDJBio Co., LTD. | Rheumatoid Arthritis (RA) | 12/25 | 12/26 | | |
LIBERTY, NCT06716814: Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa |
|
|
| Not yet recruiting | 3 | 78 | Europe | Efanesoctocog alfa, BIVV001, Altuvoct, Altuviiio, Recombinant coagulation factor VIII Fc-von-Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN) | Swedish Orphan Biovitrum, PSI CRO | Severe Haemophilia A | 08/26 | 08/26 | | |
NCT06672016: Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential |
|
|
| Recruiting | 3 | 1500 | US | Transdermal system containing progestin | Mylan Pharmaceuticals Inc | Female Contraception | 03/27 | 04/27 | | |
| Active, not recruiting | 3 | 899 | Europe, Canada, Japan, US, RoW | Tafasitamab, Monjuvi, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo | Incyte Corporation | Diffuse Large B-cell Lymphoma | 06/25 | 05/26 | | |
|
|
|
| Completed | 3 | 1 | US | StrataGraft | Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority | Skin Wound, Burns, Trauma-related Wound | 05/24 | 05/24 | | |
| Active, not recruiting | 3 | 490 | Europe, Japan, RoW | Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel | Daiichi Sankyo, AstraZeneca | Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 10/25 | 02/26 | | |
|
|
|
|
NCT05847348: 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients |
|
|
| Recruiting | 3 | 110 | RoW | 68Ga-PSMA-11, Illucix, gallium Ga 68 Gozetotide, PET/CT or PET/MRI, Imaging by PET | Telix Pharmaceuticals (Innovations) Pty Limited, Grand Pharmaceutical (China) Co., Ltd. | Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma | 12/25 | 07/26 | | |
| Active, not recruiting | 3 | 1600 | Europe, Canada, Japan, US, RoW | DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1) | Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI) | HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer | 12/25 | 12/30 | | |
|
|
FREEDOM, NCT05817812: A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa |
|
|
| Active, not recruiting | 3 | 93 | Europe, RoW | Efanesoctocog alfa, BIVV001 | Swedish Orphan Biovitrum, Syneos Health | Hemophilia A, Severe | 05/26 | 05/26 | | |
TROPION-Lung07, NCT05555732: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1170 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA®, Pemetrexed, Alimta, Pemfexy, Carboplatin, Cisplatin | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 08/27 | 08/27 | | |
DESTINY-Breast15, NCT05950945: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 250 | Europe, US, RoW | Trastuzumab Deruxtecan, T-DXd, DS-8201a (trastuzumab derextecan), Enhertu® | Daiichi Sankyo, AstraZeneca | Breast Cancer | 10/27 | 10/27 | | |
| Recruiting | 3 | 740 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA® | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 02/28 | 04/28 | | |
|
|
ARTEMIS, NCT04797884: Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 2/3 | 166 | US | TheraBionic Device, Placebo Device, Quality of Life Assessment | THERABIONIC INC., National Cancer Institute (NCI) | Hepatocellular Carcinoma | 10/24 | 10/24 | | |
FORTIFI-HN01, NCT06788990: a Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC |
|
|
| Recruiting | 2/3 | 650 | US | Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo | Bicara Therapeutics | Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | 04/28 | 07/29 | | |
TRIPHASE, NCT06101745: Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery |
|
|
| Recruiting | 2/3 | 336 | Europe | Nizaracianine Triflutate, ZW800-1, Placebo Comparator, Sugar | Curadel Surgical Innovations, Inc., Leiden University Medical Center, Erasmus Medical Center | Injury of Ureter During Surgery (Disorder) | 10/25 | 11/25 | | |
| Terminated | 2 | 16 | Europe, Canada, US, RoW | Belcesiran, Placebo | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Alpha 1-Antitrypsin Deficiency | 12/23 | 05/24 | | |
AAVIATE, NCT04514653: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) |
|
|
| Recruiting | 2 | 115 | US | Ranibizumab, RGX-314 Dose 1, Combination Product, RGX-314 Dose 2, RGX-314 Dose 3, Local Steroid, Topical Steroid | AbbVie, AbbVie | Neovascular Age-Related Macular Degeneration (nAMD) | 10/25 | 08/26 | | |
| Completed | 2 | 60 | US | RGX-314 | AbbVie | Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration | 10/23 | 03/24 | | |
Orchid 1, NCT06132919: Efficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS) |
|
|
| Recruiting | 2 | 40 | Europe | MC2-25 cream, MC2-25 vehicle | MC2 Therapeutics | Vulvar Lichen Sclerosus | 11/24 | 11/24 | | |
| Completed | 2 | 13 | US | AG Tx, Meshed Autograft, SOMA Tx, StrataGraft skin tissue Overlay of Meshed Autograft (SOMA) | Stratatech, a Mallinckrodt Company | Full Thickness Thermal Burn | 03/24 | 03/24 | | |
| Recruiting | 2 | 400 | Europe, Japan, US, RoW | HER3-DXd, Patritumab Deruxtecan, U3-1402 | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer | 06/25 | 04/26 | | |
NCT05198310 / 2022-000169-42: Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor |
|
|
| Completed | 2 | 145 | Europe, US, RoW | KPL-404, abiprubart, Placebo | Kiniksa Pharmaceuticals, Ltd., Kiniksa Pharmaceuticals, Ltd. | Arthritis, Rheumatoid | 02/24 | 05/24 | | |
